Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +60

Intuitive Surgical stock pairs growth with antitrust charge

Antitrust case Earnings report AI-generated analysis

πŸ“ˆ Intuitive Surgical revenue surged 22 percent year-over-year to USD 3.05 billion in the third quarter.

πŸ”¬ Worldwide procedures on da Vinci and Ion platforms increased approximately 15 percent, with Ion specifically up 31 percent.

πŸ₯ The company placed 546 da Vinci surgical systems in the quarter, including 315 of the newer da Vinci 5 models.

πŸ“Š The installed base grew to 12,094 da Vinci systems and 1,152 Ion systems, reflecting strong market penetration.

πŸ’° Instruments and accessories revenue reached USD 1.80 billion, an 18 percent increase driven by procedure volume.

βš–οΈ A proposed antitrust settlement resulted in a USD 450 million pre-tax charge against reported GAAP earnings.

πŸ“‰ GAAP net income per diluted share fell to USD 1.49 due to the legal charge, dropping from USD 1.95 a year ago.

πŸš€ Non-GAAP net income per diluted share increased to USD 3.00, excluding the one-time settlement impact.

🎯 Management forecasts da Vinci procedure growth near the midpoint of its 14 to 15 percent range for 2026.

πŸ’Ή Projected non-GAAP gross margins are expected to remain strong between 68.7 and 69.3 percent in 2026.

πŸ“‰ The antitrust agreement includes injunctive relief but explicitly does not admit liability or wrongdoing by the company.

πŸ“ˆ Intuitive Surgical stock traded at EUR 425.08 on Lang & Schwarz following the earnings announcement.

Bullish Signals
  • Intuitive Surgical achieved a 22 percent year-over-year revenue increase to USD 3.05 billion, demonstrating strong top-line growth.
  • Worldwide procedures expanded by approximately 15 percent, with Ion platform procedures surging 31 percent year-over-year.
  • The company placed 546 da Vinci surgical systems in the quarter, a significant increase from the 427 placed in the prior-year period.
  • Non-GAAP net income per diluted share rose to USD 3.00, reflecting underlying operational strength despite legal charges.
  • The installed base of da Vinci systems grew 12 percent to 12,094 units, providing a solid foundation for recurring revenue.
  • Management reaffirmed its guidance for 2026 da Vinci procedure growth near the midpoint of the 14 to 15 percent range.
  • Projected non-GAAP gross margins are expected to remain robust between 68.7 and 69.3 percent in 2026.
Risk Factors
  • A proposed antitrust settlement resulted in a USD 450 million pre-tax charge, significantly reducing reported GAAP net income.
  • GAAP net income per diluted share fell to USD 1.49 from USD 1.95 year-over-year due to the legal settlement impact.
  • The antitrust agreement includes injunctive relief that may impose operational constraints, though no admission of liability was made.
Full Analysis
Intuitive Surgical reported strong third-quarter financial results driven by significant growth in its core surgical platforms, though reported earnings were impacted by a proposed antitrust settlement. The company posted revenue of USD 3.05 billion, representing a 22 percent year-over-year increase, with worldwide procedures on the da Vinci and Ion systems rising approximately 15 percent. Operational metrics highlighted robust demand for Intuitive Surgical's robotic surgery solutions, with 546 da Vinci surgical systems placed during the quarter compared to 427 in the prior year. The installed base expanded by 12 percent to 12,094 da Vinci systems and grew 21 percent to 1,152 Ion systems, indicating a healthy recurring revenue environment supported by instrument sales. Despite a USD 450 million pre-tax charge related to the antitrust litigation settlement, which did not include an admission of liability, Intuitive Surgical's non-GAAP net income rose to USD 3.00 per diluted share. Management maintains positive guidance for 2026, projecting da Vinci procedure growth near the midpoint of its 14 to 15 percent range and gross margins between 68.7 and 69.3 percent. Intuitive Surgical stock traded at EUR 425.08 on Lang & Schwarz following the earnings release. The company's ability to balance organic procedure expansion with the financial weight of legal settlements remains a key factor for investors evaluating its long-term trajectory in the medical technology sector.